Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	116.59	105.76	113.45	102.29
Revenue Growth (YoY)	10.24%	-6.78%	10.91%	-
Cost of Revenue	5.42	3.88	4.64	4.79
Gross Profit	111.17	101.87	108.81	97.5
Selling, General & Admin	85.98	73.62	75.82	71.61
Research & Development	13.7	12.02	13.78	16.69
Operating Expenses	99.68	85.64	89.6	88.29
Operating Income	11.49	16.23	19.21	9.2
Interest & Investment Income	1.75	1.55	1.04	0.73
Earnings From Equity Investments	-0.08	-0.04	-1.31	-0.25
Currency Exchange Gain (Loss)	-	-	-1.5	-4.9
Other Non Operating Income (Expenses)	0.48	5.45	-8.97	3.73
EBT Excluding Unusual Items	13.64	23.18	8.48	8.51
Gain (Loss) on Sale of Assets	-0	-0.07	-3.34	-
Other Unusual Items	0.8	0.1	1	0.9
Pretax Income	14.44	23.22	-76.97	9.41
Income Tax Expense	4.56	5.32	8.52	5.1
Earnings From Continuing Operations	9.88	17.9	-85.48	4.31
Minority Interest in Earnings	-4.85	-5.81	-7.45	-2.01
Net Income	5.03	12.09	-92.93	2.3
Net Income to Common	5.03	12.09	-92.93	2.3
Net Income Growth	-58.40%	-	-	-
Shares Outstanding (Basic)	89	85	66	64
Shares Outstanding (Diluted)	103	102	66	76
Shares Change (YoY)	0.87%	55.39%	-13.02%	-
EPS (Basic)	0.06	0.14	-1.41	0.04
EPS (Diluted)	0.02	0.05	-1.41	0.03
EPS Growth	-53.23%	-	-	-
Free Cash Flow	-0.18	-5.96	17.38	5.69
Free Cash Flow Per Share	-0.00	-0.06	0.26	0.07
Gross Margin	95.36%	96.33%	95.91%	95.31%
Operating Margin	9.86%	15.35%	16.93%	9.00%
Profit Margin	4.31%	11.43%	-81.92%	2.25%
Free Cash Flow Margin	-0.15%	-5.63%	15.32%	5.56%
EBITDA	14.01	17.82	20.33	10.33
EBITDA Margin	12.02%	16.85%	17.92%	10.10%
D&A For EBITDA	2.52	1.59	1.11	1.13
EBIT	11.49	16.23	19.21	9.2
EBIT Margin	9.86%	15.35%	16.93%	9.00%
Effective Tax Rate	31.56%	22.91%	-	54.16%

Source: S&P Capital IQ. Standard template. Financial Sources.